Advertisement
Home »

Outcomes with panobinostat in heavily pretreated multiple myeloma patients.

Apr 03, 2023

ABOUT THE CONTRIBUTORS

  • Darren Pan

    Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: darren.pan@mountsinai.org.

    Tarek H Mouhieddine

    Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

    Ranjan Upadhyay

    Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

    Nicole Casasanta

    Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

    Angela Lee

    Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

    Nicole Zubizarreta

    Department of Population Health Science and Policy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

    Erin Moshier

    Department of Population Health Science and Policy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

    Joshua Richter

    Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement